These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29161753)

  • 1. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
    Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
    BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
    Besse A; Sedlarikova L; Buechler L; Kraus M; Yang CH; Strakova N; Soucek K; Navratil J; Svoboda M; Welm AL; Joerger M; Driessen C; Besse L
    Br J Cancer; 2024 Sep; 131(5):918-930. PubMed ID: 38969867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
    Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
    Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
    Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
    Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
    Kim JY; Park YJ; Lee BM; Yoon S
    Anticancer Res; 2019 Jul; 39(7):3757-3765. PubMed ID: 31262902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
    Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
    Lucia MB; Anu R; Handley M; Gillet JP; Wu CP; De Donatis GM; Cauda R; Gottesman MM
    Br J Cancer; 2011 Aug; 105(4):513-22. PubMed ID: 21829205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
    Okubo K; Isono M; Asano T; Sato A
    Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
    Bruning A; Vogel M; Mylonas I; Friese K; Burges A
    Curr Cancer Drug Targets; 2011 Sep; 11(7):799-809. PubMed ID: 21762082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.
    Kraus M; Bader J; Overkleeft H; Driessen C
    Blood Cancer J; 2013 Mar; 3(3):e103. PubMed ID: 23454896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
    Besse L; Kraus M; Besse A; Driessen C; Tarantino I
    Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
    Driessen C; Müller R; Novak U; Cantoni N; Betticher D; Mach N; Rüfer A; Mey U; Samaras P; Ribi K; Besse L; Besse A; Berset C; Rondeau S; Hawle H; Hitz F; Pabst T; Zander T
    Blood; 2018 Nov; 132(19):2097-2100. PubMed ID: 30237154
    [No Abstract]   [Full Text] [Related]  

  • 18. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.
    Piccinini M; Rinaudo MT; Anselmino A; Buccinnà B; Ramondetti C; Dematteis A; Ricotti E; Palmisano L; Mostert M; Tovo PA
    Antivir Ther; 2005; 10(2):215-23. PubMed ID: 15865215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary evidence of the mechanisms of action of HIV aspartyl peptidase inhibitors on Trypanosoma cruzi trypomastigote forms.
    Sangenito LS; Menna-Barreto RFS; Oliveira AC; d'Avila-Levy CM; Branquinha MH; Santos ALS
    Int J Antimicrob Agents; 2018 Aug; 52(2):185-194. PubMed ID: 29635008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.